Olaparib in Patients With HRD Malignant Mesothelioma

In this study, researchers will give olaparib (a drug) to mesothelioma patients who have specific changes in their DNA (known as gene mutations). Researchers will give this drug to each patient on the study to find out if it will help the patient's tumor shrink or stop growing.

Trial Details

NCT ID
NCT04515836
Phase
PHASE2
Sponsor
University of Chicago
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Olaparib
Locations (sample)
  • Chicago, Illinois, United States|41.85003,-87.65005

Key Eligibility Criteria

  • Must have a medical diagnosis of malignant mesothelioma that has been confirmed by a physician.
  • Participant must be able to sign a consent form stating that they choose (of their own free will) to participate in the study and agree to follow t…
  • Must be willing to sign and date consent form before any mandatory study-specific procedures, sample collecting and tests.
  • Willing to experience genetic testing to determine study eligibility. Must be willing to genetically test tumor and normal body cells.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →